A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection

United European Gastroenterol J. 2019 Oct;7(8):1051-1063. doi: 10.1177/2050640619854587. Epub 2019 May 27.

Abstract

Background: Recurrence remains a challenge in Clostridium difficile infection (CDI), and in this field fecal microbiota transplantation (FMT) has attracted significant interest. Network meta-analysis (NWM) has been established as an evidence-synthesis tool that incorporates direct and indirect evidence in a collection of randomized controlled trials. So far no NWM exists concerning therapeutic interventions for recurrent CDI (rCDI).

Objective: In this NWM we assessed the comparative effectiveness of various therapies for rCDI to examine the efficacy rank order and determine the optimum therapeutic approach.

Methods: A Bayesian network meta-analysis was performed to investigate the efficacy rank order of rCDI interventions.

Results: Six eligible RCTs were entered into an NWM. They included 348 rCDI patients, in whom seven therapeutic interventions were used, i.e. donor fecal microbiota transplantation (DFMT), vancomycin, fidaxomicin, vancomycin + DFMT, vancomycin + bowel lavage, autologous FMT and placebo. DFMT showed the highest efficacy in comparison with vancomycin [odds ratio (95% credible interval), 20.02 (7.05-70.03)] and fidaxomicin (22.01 (4.38-109.63)).

Conclusion: This NWM showed that DFMT is the optimum therapeutic approach for rCDI, as it was the most efficacious among various therapeutic interventions, particularly in comparison with commonly used antibiotics such as vancomycin or fidaxomicin.

Keywords: Fecal microbiota transplantation; network meta-analysis; recurrent Clostridium difficile infection; treatment.

Publication types

  • Comparative Study
  • Meta-Analysis

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides difficile / drug effects*
  • Clostridium Infections / epidemiology
  • Clostridium Infections / microbiology*
  • Clostridium Infections / therapy*
  • Combined Modality Therapy / methods
  • Fecal Microbiota Transplantation / methods*
  • Female
  • Fidaxomicin / therapeutic use
  • Humans
  • Middle Aged
  • Network Meta-Analysis
  • Placebos / administration & dosage
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Treatment Outcome
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Placebos
  • Vancomycin
  • Fidaxomicin